Sanara MedTech Future Growth
Future criteria checks 1/6
Sanara MedTech is forecast to grow earnings and revenue by 8.4% and 17.1% per annum respectively while EPS is expected to grow by 13.3% per annum.
Key information
8.4%
Earnings growth rate
13.3%
EPS growth rate
Medical Equipment earnings growth | 16.5% |
Revenue growth rate | 17.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 23 Dec 2024 |
Recent future growth updates
US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results
Nov 15Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results
Mar 22Recent updates
Sanara MedTech (NASDAQ:SMTI) Is Carrying A Fair Bit Of Debt
Dec 19US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results
Nov 15Sanara MedTech Inc. (NASDAQ:SMTI) Looks Just Right With A 28% Price Jump
Sep 05Here's Why Sanara MedTech (NASDAQ:SMTI) Can Afford Some Debt
Aug 14Sanara MedTech Inc.'s (NASDAQ:SMTI) Shares Not Telling The Full Story
May 23Is Sanara MedTech (NASDAQ:SMTI) Using Too Much Debt?
Nov 15Investors Still Waiting For A Pull Back In Sanara MedTech Inc. (NASDAQ:SMTI)
May 22Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results
Mar 22Sanara MedTech: Differentiated Offering With Niche Wound Care Exposure
Sep 06Sanara MedTech reports Q2 results
Aug 15Here's Why We're Not At All Concerned With Sanara MedTech's (NASDAQ:SMTI) Cash Burn Situation
Dec 31Sanara MedTech: Technology For Faster Healing Wounds
Dec 08Sanara Medtech inks exclusive partnership with Pixalere Healthcare
Jun 04Companies Like Sanara MedTech (NASDAQ:SMTI) Can Afford To Invest In Growth
May 18Neil Cataldi From Blueprint Discusses Sanara MedTech
May 03The Sanara MedTech (NASDAQ:SMTI) Share Price Has Soared 510%, Delighting Many Shareholders
Feb 19Is Sanara MedTech Inc. (NASDAQ:SMTI) Popular Amongst Insiders?
Dec 28Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 112 | -7 | N/A | N/A | 1 |
12/31/2025 | 103 | -9 | N/A | 1 | 2 |
12/31/2024 | 83 | -11 | N/A | -1 | 2 |
9/30/2024 | 78 | -8 | -2 | -2 | N/A |
6/30/2024 | 72 | -7 | -3 | -3 | N/A |
3/31/2024 | 68 | -5 | -3 | -3 | N/A |
12/31/2023 | 65 | -4 | -4 | -3 | N/A |
9/30/2023 | 63 | -8 | -3 | -3 | N/A |
6/30/2023 | 60 | -9 | -4 | -6 | N/A |
3/31/2023 | 54 | -6 | -6 | -5 | N/A |
12/31/2022 | 46 | -8 | -6 | -6 | N/A |
9/30/2022 | 38 | -7 | -8 | -7 | N/A |
6/30/2022 | 30 | -8 | -9 | -6 | N/A |
3/31/2022 | 27 | -10 | -6 | -6 | N/A |
12/31/2021 | 24 | -8 | -6 | -5 | N/A |
9/30/2021 | 22 | -5 | -5 | -4 | N/A |
6/30/2021 | 20 | -4 | -3 | -3 | N/A |
3/31/2021 | 17 | -4 | -4 | -3 | N/A |
12/31/2020 | 16 | -4 | -6 | -4 | N/A |
9/30/2020 | 14 | -6 | -6 | -4 | N/A |
6/30/2020 | 13 | -5 | -6 | -4 | N/A |
3/31/2020 | 13 | -4 | -6 | -4 | N/A |
12/31/2019 | 12 | -3 | -4 | -2 | N/A |
9/30/2019 | 11 | -1 | -2 | -1 | N/A |
6/30/2019 | 10 | 0 | -1 | -1 | N/A |
3/31/2019 | 9 | 0 | 0 | 0 | N/A |
12/31/2018 | 9 | 0 | 0 | 1 | N/A |
9/30/2018 | 8 | 0 | 1 | 1 | N/A |
6/30/2018 | 7 | 0 | N/A | 0 | N/A |
3/31/2018 | 7 | 0 | N/A | 0 | N/A |
12/31/2017 | 6 | 0 | N/A | 0 | N/A |
9/30/2017 | 6 | 0 | N/A | 0 | N/A |
6/30/2017 | 6 | 0 | N/A | 1 | N/A |
3/31/2017 | 6 | -1 | N/A | 0 | N/A |
12/31/2016 | 6 | -1 | N/A | 0 | N/A |
9/30/2016 | 4 | -1 | N/A | 0 | N/A |
6/30/2016 | 4 | -2 | N/A | -1 | N/A |
3/31/2016 | 3 | -1 | N/A | -1 | N/A |
12/31/2015 | 3 | -2 | N/A | -1 | N/A |
9/30/2015 | 3 | -1 | N/A | -1 | N/A |
6/30/2015 | 3 | -2 | N/A | -1 | N/A |
3/31/2015 | 3 | -2 | N/A | -1 | N/A |
12/31/2014 | 3 | -3 | N/A | -2 | N/A |
9/30/2014 | 2 | -4 | N/A | -2 | N/A |
6/30/2014 | 2 | -5 | N/A | -2 | N/A |
3/31/2014 | 2 | -4 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SMTI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SMTI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SMTI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SMTI's revenue (17.1% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: SMTI's revenue (17.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SMTI's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/06 03:25 |
End of Day Share Price | 2025/01/06 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sanara MedTech Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ross Osborn | Cantor Fitzgerald & Co. |
Yi Chen | H.C. Wainwright & Co. |